Key statistics dashboard for Rocket Pharmaceuticals, Inc. (RCKT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs.
Stock Data
| Price | $3.48 |
| Market Cap | $380M |
| Enterprise Value | $180.3M |
| Beta | 0.57 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -21.90 |
| Price / Book | 1.07 |
| P/S | 0.00 |
| EV/EBITDA | 22.67 |
| EV/Sales | 0.00 |
| EV/FCF | -1.06 |
| P/FCF | -2.25 |
| Earnings Yield | -4.39% |
| FCF Yield | -44.84% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -5.76% |
| Return on Assets | -4.08% |
| Return on Invested Capital | -48.55% |
| Return on Capital Employed | -48.92% |
Financial Health
| Current Ratio | 9.24 |
| Quick Ratio | 9.24 |
| Cash Ratio | 7.17 |
| Debt / Equity | 0.07 |
| Debt / Assets | 5.86% |
| Net Debt / EBITDA | -25.12 |
| Interest Coverage | -40.53 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 3.27 |
| Cash per share | 2.51 |
| FCF per share | -1.51 |
| Tangible Book Value per share | 2.70 |
| Dividend per share | 0.00 |
Related companies: ANNX · AURA · AUTL · DBVT · DSGN · GALT · IMAB
Explore sector: Healthcare · Biotechnology
More sections of RCKT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks